Pharmaceutical Products M&A Transactions

Sycamore Partners in advanced talks to sell Boots to the Weston family for $9 billion. Explore the implications for the UK retail sector.

Sycamore Partners in advanced talks with Wittington Investments for a $9 billion sale of Boots, marking a significant retail sector transaction.

Clarenta Group strengthens early-stage drug development with the acquisition of Leads To Development, integrating preclinical and regulatory expertise.

Webster Equity Partners to acquire Lifecore Biomedical in a deal valued up to $663.7M, enhancing its position in sterile injectable pharmaceutical manufacturing.

AVS Bio, a portfolio company of Arlington Capital Partners, has acquired Biorbyt Ltd., enhancing its biomaterials offerings and global reach in life sciences research.

Dabur India

Dabur India's merger with Sesa Care gains NCLT approval, enhancing its Ayurvedic hair care offerings and market reach. Learn more about this strategic integration.

Kobayashi Pharmaceutical

Private equity firms CVC Capital Partners and NSSK are in talks for a potential $3.2 billion acquisition of Japanese healthcare firm Kobayashi Pharmaceutical.

Copeland strengthens its healthcare and life sciences cold chain capabilities by acquiring environmental monitoring specialist Dickson.

Grünenthal secures Stivarga® cancer treatment from Bayer AG for up to €375 million, enhancing its oncology pipeline and global market presence.